Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer

Study summary

The purpose of this study is to learn whether it is better to receive the drug Metformin with standard of care for lung cancer or just standard of care.

Ask AI to explain this study

Start here

Key things to know

Main goalPrevention

This describes the study’s primary purpose.

What is being studiedMetformin and Placebo Comparator

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Mar 10, 2020 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 2

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Mayo Clinic

Study sponsor

Study overview

What this study is about

Purpose: Prevention
Study type: Interventional
Phase: Phase 2
Sponsor: Mayo Clinic
Interventions being studied: Drug: Metformin; Other: Placebo Comparator

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Non-small cell lung cancer (NSCLC)→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Suspected or biopsy proven Stage IA-IIIA lung squamous cell carcinoma (SCC) (must be proven SCC at the time of surgery)
Medically fit for surgical resection (based on surgeon assessment)
Current or prior smoker
Age \> 18 years old
Both Male and Female
Willing and able to consent to study, undergo study interventions, and take study drug
Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, 2
Subject must start Metformin within 90 days of surgery.

Reasons someone may not be able to joinExclusion criteria

Currently taking metformin or other diabetic drugs
Current or previous congestive heart failure, renal failure or liver failure
Creatinine in Women of 1.4 or greater and Creatinine in Men of 1.5 or greater
Existing untreated or prior cancer \<5 years from diagnosis
Received neo-adjuvant platinum-based chemotherapy or targeted therapy
Receiving adjuvant platinum-based chemotherapy or targeted therapy after surgical resection

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Mayo Clinic in RochesterRochester, Minnesota

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 10, 2020. Always confirm current availability with the study team.

View original record ↗